Black Diamond Therapeutics Inc (BDTX)

May 12, 2025, 4:05 PM EDT - 1 day ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 31, 2025, 8:00 AM EDT - 6 weeks ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Mar 25, 2025, 12:58 AM EDT - 7 weeks ago

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Mar 19, 2025, 7:00 AM EDT - 7 weeks ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 13, 2025, 3:47 PM EDT - 2 months ago

Black Diamond Therapeutics: In Decline, But Why?

Mar 6, 2025, 4:01 PM EST - 2 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dec 30, 2024, 3:07 PM EST - 4 months ago

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Nov 5, 2024, 8:00 AM EST - 6 months ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 3:24 PM EDT - 7 months ago

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 7, 2024, 4:01 PM EDT - 7 months ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 7:00 AM EDT - 8 months ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 8 months ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 8 months ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 10 months ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 27, 2024, 10:38 AM EDT - 11 months ago

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 1, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 9, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 7, 2024, 6:00 PM EDT - 1 year ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Mar 24, 2024, 11:25 PM EDT - 1 year ago

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

AAPL AER AMZN BA DFH DHI GE

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 12, 2024, 5:21 PM EST - 1 year ago

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 4, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 1 year ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 14, 2023, 12:30 PM EDT - 1 year ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 12, 2023, 8:31 AM EDT - 1 year ago

Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy

Oct 4, 2023, 12:14 PM EDT - 1 year ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:53 AM EDT - 1 year ago

Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer Update

Jun 29, 2023, 8:57 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 28, 2023, 6:51 PM EDT - 2 years ago

Black Diamond: On Right Track For Possible Accelerated Approval Pathway

Jun 28, 2023, 4:23 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Jun 27, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

Jun 13, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference

May 9, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Apr 17, 2023, 4:01 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting

Mar 9, 2023, 7:30 AM EST - 2 years ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Feb 27, 2023, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

Jan 5, 2023, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 12, 2022, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company

Nov 8, 2022, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update